A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
about
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A multicenter, phase II study ...... st cancer (the HER2NAT study).
@en
type
label
A multicenter, phase II study ...... st cancer (the HER2NAT study).
@en
prefLabel
A multicenter, phase II study ...... st cancer (the HER2NAT study).
@en
P2093
P2860
P1476
A multicenter, phase II study ...... st cancer (the HER2NAT study).
@en
P2093
Futoshi Akiyama
Katsumasa Kuroi
Keiko Miyakoda
Kenjiro Aogi
Masafumi Kurosumi
Masahiro Kashiwaba
Nobuaki Sato
Norikazu Masuda
Reiki Nishimura
Seigo Nakamura
P2860
P2888
P304
P356
10.1007/S10147-012-0437-1
P577
2012-07-26T00:00:00Z